Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China

被引：0
|
作者：
Xiao, Xiang [1 ]
机构：
[1] Sichuan Univ, West China Hosp, Chengdu, Peoples R China
来源：
NEPHROLOGY DIALYSIS TRANSPLANTATION | 2024年 / 39卷
关键词：
D O I：
10.1093/ndt/gfae069.1760
中图分类号：
R3 [基础医学]; R4 [临床医学];
学科分类号：
1001 ; 1002 ; 100602 ;
摘要：
1743
引用
收藏
页数：4
相关论文
共 50 条
  • [1] Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China
    Xiao, Xiang
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39 : I2766 - I2769
  • [2] Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China
    Xiao, Xiang
    Ji, Shuming
    Zheng, Tao
    Wang, Tianzhu
    Jiang, Dapeng
    Liu, Fang
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [3] Kidney Outcomes Associated With SGLT2 Inhibitors Versus Other Glucose-Lowering Drugs in Real-world Clinical Practice: The Japan Chronic Kidney Disease Database
    Nagasu, Hajime
    Yano, Yuichiro
    Kanegae, Hiroshi
    Heerspink, Hiddo J. L.
    Nangaku, Masaomi
    Hirakawa, Yosuke
    Sugawara, Yuka
    Nakagawa, Naoki
    Tani, Yuji
    Wada, Jun
    Sugiyama, Hitoshi
    Tsuruya, Kazuhiko
    Nakano, Toshiaki
    Maruyama, Shoichi
    Wada, Takashi
    Yamagata, Kunihiro
    Narita, Ichiei
    Tamura, Kouichi
    Yanagita, Motoko
    Terada, Yoshio
    Shigematsu, Takashi
    Sofue, Tadashi
    Ito, Takafumi
    Okada, Hirokazu
    Nakashima, Naoki
    Kataoka, Hiromi
    Ohe, Kazuhiko
    Okada, Mihoko
    Itano, Seiji
    Nishiyama, Akira
    Kanda, Eiichiro
    Ueki, Kohjiro
    Kashihara, Naoki
    DIABETES CARE, 2021, 44 (11) : 2542 - 2551
  • [4] SGLT2 inhibitors: from glucose-lowering to cardiovascular benefits
    Preda, Alberto
    Montecucco, Fabrizio
    Carbone, Federico
    Camici, Giovanni G.
    Luscher, Thomas F.
    Kraler, Simon
    Liberale, Luca
    CARDIOVASCULAR RESEARCH, 2024, 120 (05) : 443 - 460
  • [5] Glucose-Lowering and Metabolic Effects of SGLT2 Inhibitors
    Mordi, Ify R.
    Lang, Chim C.
    HEART FAILURE CLINICS, 2022, 18 (04) : 529 - 538
  • [6] Risk of Venous Thromboembolism amongst Initiators of SGLT2 Inhibitors Compared with Other Glucose-Lowering Agents
    Gopalakrishnan, Chandrasekar
    Desai, Rishi J.
    Kim, Seoyoung C.
    Patorno, Elisabetta
    DIABETES, 2020, 69
  • [7] SGLT2 inhibitors and kidney outcomes in the real world
    Smith, Steven M.
    BMJ-BRITISH MEDICAL JOURNAL, 2020, 369
  • [8] Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: A real-world systematic review and meta-analysis
    Li, Chun-xing
    Liang, Shuo
    Gao, Lingyan
    Liu, Hua
    PLOS ONE, 2021, 16 (02):
  • [9] Real-Life Prescribing of SGLT2 Inhibitors: How to Handle the Other Medications, Including Glucose-Lowering Drugs and Diuretics
    Lam, David
    Shaikh, Aisha
    KIDNEY360, 2021, 2 (04): : 742 - 746
  • [10] Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs The CVD-REAL 2 Study
    Kosiborod, Mikhail
    Lam, Carolyn S. P.
    Kohsaka, Shun
    Kim, Dae Jung
    Karasik, Avraham
    Shaw, Jonathan
    Tangri, Navdeep
    Goh, Su-Yen
    Thuresson, Marcus
    Chen, Hungta
    Surmont, Filip
    Hammar, Niklas
    Fenici, Peter
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 71 (23) : 2628 - 2639
12345